9/24 GNOMX awarded BARDA contract to predict hospital readmission of sepsis patients
Disease Targets
GNOMX is developing epigenetic tests for rapid sepsis with antibiotic susceptibility guidance and sepsis hospital readmission risk. Sepsis is the primary cause of readmission to the hospital, costing more than $3.5 billion each year. GNOMX was recently awarded a Ph1 BARDA DRIVE contract to develop immune dysregulation host-based assay for predicting sepsis patient readmission risk.
GNOMX has demonstrated > 90% accuracy in a proof-of-concept study which will enable definitive diagnosis of early Lyme disease well before current serology tests. GNOMX was recently awarded a subcontract by HHS / NASA to develop its acute Lyme disease test.